Dosage forms for treatment of benign prostatic hyperplasia

Abstract

A method for treatment or prophylaxis of benign prostatic hyperplasia by administration of lonidarrine or a lonidamine analog is provided. Also provided are unit dosage forms of lonidamine or an analog, useful for such treatment and prophylaxis.

1 . A unit dose formulation of lonidamine that is not a 150 mg tablet.  
     
     
         2 . A unit dose formulation of lonidamine comprising an amount of lonidamine in the range of 10 mg to 100 mg or in the range of 200 mg to 5000 mg.  
     
     
         3 . A unit dose formulation of lonidamine that is not an oral dosage form.  
     
     
         4 . A unit dose formulation of lonidamine that is not in the form of a pill, tablet, capsule, caplet, troche, elixir, oral suspension, syrup, wafer, or lozenge.  
     
     
         5 . A unit dose formulation of a lonidamine analog.  
     
     
         6 . A sustained release formulation of lonidamine or a lonidamine analog.  
     
     
         7 . The sustained release formulation of  claim 6  that comprises 
 (a) a reservoir system;    (b) a matrix system;    (c) a microencapsulation system;    (d) a coated granule system;    (e) a solvent-activated system; or,    (f) a polymeric degradation system.    
     
     
         8 . A method for treating or preventing benign prostatic hypertrophy (BPH) comprising administering the formulation of any of claims  1 - 7  to a human subject in need of such treatment or prevention.